MedTrace Logo

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

NCT05790889 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2025-03-07

No results posted yet for this study

Summary

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso

Conditions

  • Malaria,Falciparum

Interventions

BIOLOGICAL

Rabies vaccine

Vaccine

BIOLOGICAL

RH5.1 10μg adjuvated with 50μg Matrix-M

Vaccine

BIOLOGICAL

RH5.2 5μg adjuvated with 50μg Matrix-M

Vaccine

Sponsors & Collaborators

  • Institut de Recherche en Sciences de la Sante, Burkina Faso

    collaborator OTHER_GOV

  • European and Developing Countries Clinical Trials Partnership (EDCTP)

    collaborator OTHER_GOV

  • Wellcome Trust

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela Minassian · Honorary Consultant and Chief Investigator - Project clinical trials

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Months
Max Age
17 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2026-05-30
Completion
2026-05-30

Countries

  • Burkina Faso

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05790889 on ClinicalTrials.gov